Ireland established specific regulatory guidelines for wastewaters from pharmaceutical production sites. The
treatment process combination of MBR followed by Ozone has proven its availability to fulfill the regulatory
requirements. The in Ireland installed WWTP is meeting the original design goals to reduce APIs in the site’s
final effluent and sets a new benchmark for full-scale pharmaceutical manufacturing wastewater treatment.
In summary the WWTP reduces total APIs from the wastewater by 99.94%; reduces estrogenicity 1,000
fold to a level believed to be of no concern to human health or to the environment; and produces a nontoxic
effluent. Additionally, it was shown that this treated effluent could be beneficially reclaimed as makeup
water for cooling towers and potentially for other beneficial reuse purposes.